Industry Reports

Puma Biotechnology and Pint Pharma International have entered into an agreement for Pint Pharma to commercialize NERLYNX (neratinib) in Argentina, Brazil, Chile, Colombia, Mexico and…
Read More...

Clinipace Worldwide has announced the appointment of Ian Fraser as senior vice president of operations for the European Union and Middle East (EUME). In his new role, Fraser will lead…
Read More...

Acerus Pharmaceuticals Corporation announced that it has entered into an exclusive distributor and license agreement with Metuchen Pharmaceuticals, a privately-held specialty…
Read More...

FORMA Therapeutics announced the appointment of Frances Duffy-Warren, Ph.D., to the leadership team as Head of Regulatory Affairs. Frances brings more than 30 years of pharmaceutical…
Read More...

GlaxoSmithKline plc announces that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2…
Read More...

Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Lialda (mesalamine) delayed-release tablets, 1.2 g, in the U.S. Mesalamine delayed-release tablets…
Read More...

CutisPharma announced that it has been acquired by NovaQuest Capital Management. As a part of the transaction, Goldman Sachs Specialty Lending Group has provided financing to further…
Read More...

Merck announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck’s global legal, security and aviation, and…
Read More...

BIOASIS TECHNOLOGIES announced that Dr. Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, has been appointed as chair of the board of directors. She takes over from former board chair…
Read More...

Symbiotix Biotherapies announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix gains access to a portfolio of intellectual…
Read More...

Ionis Pharmaceuticals and Akcea Therapeutics, Inc., an affiliate of Ionis, announced an exclusive, worldwide license by Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly…
Read More...

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement,…
Read More...

Mallinckrodt plc announced it has closed the sale of RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant to Baxter International Inc. "This action further…
Read More...

Ardelyx, Inc. announced a license agreement with Knight Therapeutics, Inc. (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is…
Read More...

Nexcelom Bioscience announced that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom's worldwide growth…
Read More...

Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16…
Read More...

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, announced the promotion of…
Read More...

X-Chem, Inc. announced the appointment of Christelle Huguet, Ph.D. as Chief Scientific Officer, along with an executive leadership appointment for Matthew Clark, Ph.D. as Senior Vice…
Read More...

Dr. Reddy’s Laboratories Ltd announced that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal Allergy…
Read More...

Ionis Pharmaceuticals and Akcea Therapeutics announced an exclusive, worldwide license by Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction…
Read More...